Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma.

Cancers (Basel) · 2019 · PMC7017131 · PMID 31861548

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significancep = 0.09so close (0.05 < p ≤ 0.1)

63%), and a slight PFS advantage was observed in the triplet arm that nonetheless did not reach statistical significance (median, 9.7 vs. 6.9 months, HR 0.72, p = 0.09) [ 71 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.